Related references
Note: Only part of the references are listed.Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients
Ali T. Taher et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Iron overload in β-thalassemia intermedia: an emerging concern
Khaled M. Musallam et al.
CURRENT OPINION IN HEMATOLOGY (2013)
Iron Overload and Glucose Metabolism in Subjects with β-thalassaemia Major : An Overview
Vincenzo De Sanctis et al.
CURRENT DIABETES REVIEWS (2013)
Iron chelation therapy in thalassemia major: A systematic review with meta-analyses of 1520 patients included on randomized clinical trials
Aurelio Maggio et al.
BLOOD CELLS MOLECULES AND DISEASES (2011)
Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia
Khaled M. Musallam et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major
Kallistheni Farmaki et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Anemia, Ineffective Erythropoiesis, and Hepcidin: Interacting Factors in Abnormal Iron Metabolism Leading to Iron Overload in β-Thalassemia
Sara Gardenghi et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2010)
Levels of non-transferrin-bound iron as an index of iron overload in patients with thalassaemia intermedia
Ali Taher et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Spleen R2 and R2* in Iron-Overloaded Patients With Sickle Cell Disease and Thalassemia Major
Casey J. Brewer et al.
JOURNAL OF MAGNETIC RESONANCE IMAGING (2009)
Inflammation and oxidant-stress in β-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial
Patrick B. Walter et al.
HAEMATOLOGICA (2008)
The evolution of iron chelators for the treatment of iron overload disease and cancer
DS Kalinowski et al.
PHARMACOLOGICAL REVIEWS (2005)
Safety and effectiveness of 100 mg/kg/day deferiprone in patients with thalassemia major: A two-year study
A Taher et al.
ACTA HAEMATOLOGICA (2005)
Complications of β-thalassemia major in north America
MJ Cunningham et al.
BLOOD (2004)
Assessment of thyroid function in two hundred patients with β-thalassemia major
A Zervas et al.
THYROID (2002)
Endocrine complications in patients with β-thalassemia major
Y Aydinok et al.
JOURNAL OF TROPICAL PEDIATRICS (2002)
Hepatic iron concentration and total body iron stores in thalassemia major.
E Angelucci et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
